A growing number of drugmakers in China are on a quest to treat NASH
Minhua Chu · 12/01/2022
Currently, 30 potential NASH drugs are in clinical studies in China, another eight candidates have submitted IND applications while six have already been greenlighted.
READ MORE

Latest Articles

Kintor Pharma announces it has met its primary endpoint in a phase II clinical study for KX-826 in China; Innovent Biologics, InnoBM Pharmaceuticals
Sarina Yang · 2 days ago
Kintor Pharma announced the results of a phase II clinical trial of pyrilutamide (KX-826) for treating adult female androgenetic alopecia (AGA). More news from Innovent Biologics, InnoBM Pharmaceuticals.
News
Boan Biotech files IPO application with HKEX
Sarina Yang · 3 days ago
The Hong Kong Stock Exchange (HKEX) announced that it has accepted an IPO application from Boan Biotech.
News
A growing number of drugmakers in China are on a quest to treat NASH
Minhua Chu · 4 days ago
Currently, 30 potential NASH drugs are in clinical studies in China, another eight candidates have submitted IND applications while six have already been greenlighted.
Feature
Fosun subsidiary Gland Pharma to acquire Cenexi
Sarina Yang · 4 days ago
Fosun Pharma announced yesterday that its subsidiary Gland Pharma intend to acquire Cenexi Group, a European CDMO company, for a consideration not exceeding EUR 210 million.
News
Full-Life Technologies acquires Focus-X for $245 million; Trinomab, Polymed Biopharmaceuticals, Pediatrix Therapeutics, CSL Vifor
Danni Yin · 5 days ago
Full-Life Technologies announced that it has signed an agreement to acquire Focus-X Therapeutics to expand its radiopharmaceuticals pipeline.
News
Sirona Biochem partners with Wanbang Biopharmaceuticals for diabetes treatment; Fosun Kite
Sarina Yang · 6 days ago
Sirona Biochem announced that it has signed an expanded international agreement with Wanbang Biopharmaceuticals to collaborate on licensing TFC-039, Sirona’s SGLT2 inhibitor, for treating both animals and humans. More news from Fosun Kite.
News
A slow October sees deals in novel therapies with new technologies
Shi Yingzi · 7 days ago
​October was another slow month for licensing deals in China, with a total, once again, of only seven. Three of them were in-licensing deals with overseas companies.
China Deals Tracker
ADC drug discovery companies PrimeLink and Xiling Lab close financing rounds; Hengrui Pharma, Blueprint Medicines, CStone
Sarina Yang · 9 days ago
PrimeLink and Xiling Lab, two ADC drug discovery companies, have just closed financing rounds. More news from Hengrui Pharma, Blueprint Medicines, CStone.
News
Not so kind: Kind Pharmaceuticals faces FibroGen’s legal wrath for allegedly stealing anemia drug IP
Minhua Chu · 10 days ago
On November 14, FibroGen filed a federal lawsuit in California alleging that two of its former employees stole its anemia treatment work and established company in China to develop me-too drugs and apply for patents.
Feature
ViroTech secures a strategic investment of RMB 100 million from NKY Medical; Angalbio, BeyondSpring, Ascletis Pharma, Frontier Biotechnologies
Danni Yin · 10 days ago
ViroTech Pharmaceutical has received a strategic investment of RMB 100 million from NKY Medical. NKY will hold 10.42% of ViroTech’s shares after the investment is completed.
News
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement